Focused On-demand Library for Segment polarity protein dishevelled homolog DVL-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O14640

UPID:

DVL1_HUMAN

Alternative names:

DSH homolog 1

Alternative UPACC:

O14640; Q5TA33; Q5TA35

Background:

Segment polarity protein dishevelled homolog DVL-1, also known as DSH homolog 1, is a pivotal component in the Wnt signaling pathway. It binds to the cytoplasmic C-terminus of frizzled family members, facilitating both canonical and non-canonical Wnt signaling. This protein is essential for LEF1 activation through WNT1 and WNT3A signaling and plays a critical role in the neuromuscular junction formation by forming a ternary complex with DVL1 and PAK1.

Therapeutic significance:

DVL-1's involvement in Robinow syndrome, autosomal dominant 2, a rare skeletal dysplasia syndrome, underscores its therapeutic significance. Understanding the role of DVL-1 could open doors to potential therapeutic strategies for treating this condition, which is characterized by distinctive dysmorphic features, limb shortening, and renal anomalies.